Serbian
Polymer Drugs in the Clinical Stage
Overview of attention for book
Table of Contents
-
Altmetric BadgeBook Overview
-
Altmetric BadgeChapter 1 Challenges in Polymer Therapeutics
-
Altmetric BadgeChapter 2 Factors and Mechanism of “EPR” Effect and the Enhanced Antitumor Effects of Macromolecular Drugs Including SMANCS
-
Altmetric BadgeChapter 3 PEG-Adenosine Deaminase and PEG-Asparaginase
-
Altmetric BadgeChapter 4 Peginterferon alfa-2a (40KD): A Potent Long-Acting Form of Interferon alfa-2a for the Treatment of Hepatitis C
-
Altmetric BadgeChapter 5 PEG-Methioninase
-
Altmetric BadgeChapter 6 Poly-(L)-Glutamic Acid-Paclitaxel (CT-2103) [XYOTAX™], a Biodegradable Polymeric Drug Conjugate
-
Altmetric BadgeChapter 7 HPMA Copolymer Delivery of Chemotherapy and Photodynamic Therapy in Ovarian Cancer
-
Altmetric BadgeChapter 8 Drug-HPMA-HuIg conjugates effective against human solid cancer.
-
Altmetric BadgeChapter 9 CM-Dextran-Polyalcohol-Camptothecin Conjugate
-
Altmetric BadgeChapter 10 Polymeric Micelle Drug Carrier Systems: PEG-PAsp(Dox) and Second Generation of Micellar Drugs
-
Altmetric BadgeChapter 11 An Interim Analysis of Phase I Clinical Trial of MCC-465, a Doxorubicin (DXR) Encapsulated in PEG-immunoliposome, in Patients with Metastatic Stomach Cancer
-
Altmetric BadgeChapter 12 Polymer Conjugates for Imaging
-
Altmetric BadgeChapter 13 S-Nitrosylated Polyethylene Glycol-conjugated Hemoglobin Derivative as a Candidate Material for Oxygen Therapeutics
Attention for Chapter 4:
Peginterferon alfa-2a (40KD): A Potent Long-Acting Form of Interferon alfa-2a for the Treatment of Hepatitis C